; (II) the national average drug acquisition cost of the drug; and (III) any other similar determination of pharmacy acquisition costs of the drug, as determined by the Secretary; and (ii) the maximum fair price for the drug. (D) The establishment of procedures to ensure that the maximum fair price for a selected drug is applied before— (i) any coverage or financial assistance under other health benefit plans or programs that provide coverage or financial assistance for the purchase or provision of prescription drug coverage on behalf of fair price eligible individuals as the Secretary may specify; and (ii) any other discounts. (E) The establishment of procedures to enter into appropriate agreements and protocols for the ongoing computation of AIM prices for selected drugs, including, to the extent possible, to compute the AIM price for selected drugs and including by providing that the manufacturer of such a selected drug should provide information for such computation not later than 3 months after the first date of the voluntary negotiation period for such selected drug. (F) The establishment of procedures to compute and apply the maximum fair price across different strengths and dosage forms of a selected drug that are not based on the specific formulation, dosage or strength, packaging, or form of administration. (G) The establishment of procedures to negotiate and apply the maximum fair price in a manner that does not include any dispensing or similar fee. (H) The establishment of procedures to carry out the provisions of this part with respect to— (i) fair price eligible individuals who are enrolled under a prescription drug plan under part D of title XVIII or an MA–PD plan under part C of such title